Appointed
John McAdory
Chief Operating Officer
ONCY ·
ONCOLYTICS BIOTECH INC
appointed John McAdory as Chief Operating Officer of the Company
Ready 8-Ks
28
Latest filing
October 20, 2026, 9:37 AM ET
Top materiality
0.85
Event mix
other_material ×19 · regulatory ×7 · leadership ×2
Sentiment
21 pos · 1 neg · 6 neu
Executive change
recent →
Recent 8-K filings for ONCY
Highest-materiality recent filing
Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC
- Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.
- Objective response rate 33% with pelareorep+FOLFIRI+bevacizumab, tripling the 6-11% standard of care.
-
REO 033 randomized, open-label Phase 2 study enrolls 30 patients per arm: pelareorep + FOLFIRI + bevacizumab vs FOLFIRI + bevacizumab in 2L RAS-mutant MSS mCRC.
-
Oncolytics sees final PanCAN grant payment this quarter; GOBLET Cohort 4 data due Q4 2026
Oncolytics (Nasdaq: ONCY) expects the final Pancreatic Cancer Action Network grant payment later this quarter after completing Cohort 5 wind-down activities.
-
Oncolytics says new pelareorep method-of-use patents extend IP protection into late 2040s
New method-of-use patent covering pelareorep as a cancer immunotherapy issued in several countries; corresponding U.S. patent expected in the near term.
-
Oncolytics' pelareorep data in PNAS show 'cold' liver tumors turned immunotherapy-responsive
Academic paper 'MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma' published in Proceedings of the National Academy of Sciences on Sept. 28, 2026.
-
Oncolytics: REO 033 CRC study sites nearly all activated; interim Part A data due year-end 2026
Part A of randomized REO 033 to enroll ~60 patients with second-line RAS-mutant MSS metastatic colorectal cancer; ORR is primary endpoint, with PFS, OS, safety and biomarkers.
-
Pelareorep + pan-RAS inhibitor reduced tumor growth vs control in RAS-driven colorectal cancer model.
-
Oncolytics aligns with FDA on pivotal Part B expansion for REO 033 colorectal cancer study
FDA written feedback supports potential pivotal Part B expansion of REO 033 in 2L RAS-mutant MSS colorectal cancer.
-
Oncolytics Biotech receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq letter on July 20, 2026, for non-compliance with $1.00 minimum bid price rule.
-
Oncolytics Biotech receives FDA Fast Track for pelareorep in second-line anal cancer
FDA granted Fast Track for pelareorep + checkpoint inhibitor in inoperable/metastatic squamous cell anal carcinoma after prior therapy.
-
Oncolytics: FDA Type D meeting in Aug; half of REO 033 sites activated, >20 patients pre-identified
Company to hold Type D meeting with FDA in first half of August 2026 to discuss registrational design for REO 033 Part B.
-
Oncolytics Biotech disengages EY, engages Baker Tilly as auditor after restructuring
Audit committee voted to disengage EY and engage Baker Tilly for fiscal 2026, subject to client acceptance.
-
USPTO issued patent covering pelareorep manufacturing process, expected protection into 2044.
-
Oncolytics appoints Steve Glover to board, promotes John McAdory to COO
Steve Glover appointed to board effective June 1, 2026; he chaired Ambrx during its $2B J&J acquisition.
-
Initial data in solid tumor model shows greater anti-tumor activity with pelareorep+RAS inhibitor vs either alone.
-
Data from GOBLET (advanced pancreatic cancer) and AWARE-1 (early-stage breast cancer) to be presented at ASCO 2026 May 29-June 2.
-
Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC
Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.
-
Oncolytics secures FDA alignment on pivotal anal cancer study for pelareorep
FDA agreed on a randomized controlled pivotal trial design for pelareorep in post-first-line metastatic SCAC, targeting accelerated and full approval.
-
Oncolytics Biotech enters ATM agreement for up to $75M common stock offering
Agreement with Jefferies LLC allows sale of up to $75M in common stock at market prices.
-
Oncolytics schedules Type C FDA meeting for pelareorep single-arm study in anal cancer
FDA meeting set for April 16, 2026 to discuss single-arm pivotal study of pelareorep + checkpoint inhibitor in SCAC.
-
Redomestication from Canada to Nevada completed; common stock continues trading on Nasdaq under ONCY.
-
Oncolytics completes continuance to BC; expects Nevada domestication by March 31
First step completed March 17: continuance from Alberta to British Columbia under BCBCA.
-
Pelareorep data at AACR: 62% ORR in pancreatic cancer; TLS formation in breast cancer
GOBLET cohort 1: 62% objective response rate in first-line mPDAC, more than double historical chemotherapy alone.
-
Randomized Phase 2 study (REO 033) of pelareorep + bevacizumab + FOLFIRI vs bevacizumab + FOLFIRI in 30 patients per arm.
-
Oncolytics prioritizes SCAC and CRC registration studies; GOBLET enrollment closed
Concluded enrollment in GOBLET gastrointestinal study; now focusing on registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC).
-
FDA Fast Track Designation for pelareorep + bevacizumab + FOLFIRI in second-line KRAS-mutant MSS metastatic colorectal cancer.
-
Oncolytics appoints EVP John McAdory and VP Biostatistics Yujun Wu, grants inducement awards
John McAdory named EVP Strategy & Operations; previously VP Clinical Ops at CG Oncology (Nasdaq: CGON).
-
Oncolytics shareholders OK continuance to BC and domestication to Nevada
Continuance from Alberta to British Columbia approved: 85.21% in favor.
-
GOBLET Cohort 4: 4/14 evaluable third-line anal cancer patients responded (ORR 29%), 2 CRs, 2 PRs; median DOR ~17 months vs historical ~10%.
Executive changes
Appointed
Stephen Glover
Director
ONCY ·
ONCOLYTICS BIOTECH INC
appointed Stephen Glover as the ninth director of the Board
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material